5,7-dichloro-3-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}pyrazolo[1,5-a]pyrimidine | 1420468-47-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5,7-dichloro-3-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}pyrazolo[1,5-a]pyrimidine
• 英文别名: 5,7-Dichloro-3-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}pyrazolo[1,5-a]pyrimidine；5,7-dichloro-3-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]pyrazolo[1,5-a]pyrimidine
• CAS: 1420468-47-8
• 化学式: C₁₅H₁₀Cl₂F₃N₃
• 分子量: 360.166
• InChiKey: BJNSJGFRJGMWKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5,7-dichloro-3-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}pyrazolo[1,5-a]pyrimidine 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  [3a,4]-Dihydropyrazolo[1,5a]pyrimidines: Novel, Potent, and Selective Phosphatidylinositol-3-kinase β Inhibitors

  摘要：

  A series of novel [3a,4]dihydropyrazolo[1,5a]pyrimidines were identified, which were highly potent and selective inhibitors of PI3K beta. The template afforded the opportunity to develop novel SAR for both the hinge-binding (R-3) and back-pocket (R-4) substitutents. While cellular potency was relatively modest due to high protein binding, the series displayed low clearance in rat, mouse, and monkey.

  DOI：

  10.1021/ml300330m
• 作为产物：
  描述：

  4-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-1H-pyrazol-3-amine 在 盐酸 、 sodium methylate 、 N,N-二乙基苯胺 作用下， 以 甲醇 、 水 为溶剂， 生成 5,7-dichloro-3-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}pyrazolo[1,5-a]pyrimidine
  参考文献：
  名称：

  Pyrazolopyrimidine derivatives as PI3 kinase inhibitors

  摘要：

  具有该结构的PI3Kβ选择性化合物

  公开号：

  US09096605B2

文献信息

• [EN] PYRAZOLOPYRIMIDINE DERIVATIVES AS PI3 KINASE INHIBITORS<br/>[FR] DÉRIVÉS PYRAZOLOPYRIMIDINES EN TANT QU'INHIBITEURS DE PI3 KINASE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2013028263A1

  公开（公告）日：2013-02-28

  The present invention relates to compounds of formula (I) in which R1, R2, R3 and n have the meaning given in the specification and also relates to the use of these pyrazolopyrimidine derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3'OΗ kinase family (hereinafter PI3 kinases), wherein the compounds of formula (I) are described as selective inhibitors of PI3K[beta] activity.

  本发明涉及式(I)中R1、R2、R3和n的化合物，其中R1、R2、R3和n的含义如规范中所述，并且还涉及使用这些吡唑吡嘧啶衍生物来调节磷脂酰肌醇3'羟基激酶家族（以下简称PI3激酶）的活性或功能，其中式(I)的化合物被描述为PI3K[beta]活性的选择性抑制剂。
• Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors
  申请人：GlaxoSmithKline LLC

  公开号：US20140187545A1

  公开（公告）日：2014-07-03

  PI3Kβ selective compounds having the structure

  具有以下结构的PI3Kβ选择性化合物：
• US9096605B2
  申请人：——

  公开号：US9096605B2

  公开（公告）日：2015-08-04
• Pyrazolopyrimidine derivatives as PI3 kinase inhibitors
  申请人：Lin Hong

  公开号：US09096605B2

  公开（公告）日：2015-08-04

  PI3Kβ selective compounds having the structure

  具有该结构的PI3Kβ选择性化合物
• [3<i>a</i>,4]-Dihydropyrazolo[1,5<i>a</i>]pyrimidines: Novel, Potent, and Selective Phosphatidylinositol-3-kinase β Inhibitors
  作者：Hongyi Yu、Michael L. Moore、Karl Erhard、Mary Ann Hardwicke、Hong Lin、Juan I. Luengo、Jeanelle McSurdy-Freed、Ramona Plant、Junya Qu、Kaushik Raha、Cynthia M. Rominger、Michael D. Schaber、Michael D. Spengler、Ralph A. Rivero

  DOI：10.1021/ml300330m

  日期：2013.2.14

  A series of novel [3a,4]dihydropyrazolo[1,5a]pyrimidines were identified, which were highly potent and selective inhibitors of PI3K beta. The template afforded the opportunity to develop novel SAR for both the hinge-binding (R-3) and back-pocket (R-4) substitutents. While cellular potency was relatively modest due to high protein binding, the series displayed low clearance in rat, mouse, and monkey.